Galectin drug showed no difference from placebo, The Street reports Galectin's (GALT) GR-MD-02 showed no difference from placebo across most efficacy biomarkers in a phase I study of nonalcoholic steatohepatitis, The Street's Adam Feuerstein reports. The stock is trading down 50% today to $7.24 while La Jolla (LJPC), which is developing a similar drug to treat NASH, is down 13%. Reference Link
News For GALT;LJPC From The Last 14 Days
Check below for free stories on GALT;LJPC the last two weeks.